相似文献
1
Expansion of the medical cannabis market in Brazil and regulatory challenges.巴西医用大麻市场的扩张及监管挑战。
Cad Saude Publica. 2024 Dec 20;40(11):e00088624. doi: 10.1590/0102-311XEN088624. eCollection 2024.
2
The Cannabis Gray Market: A Case for Cannabis Regulatory Science Research.大麻灰色市场：大麻监管科学研究的一个案例
Cannabis Cannabinoid Res. 2025 Feb;10(1):6-10. doi: 10.1089/can.2023.0278. Epub 2024 Jul 1.
3
Perspectives on formation of medical cannabis market in Ukraine based on holistic approach.基于整体方法对乌克兰医用大麻市场形成的见解。
J Cannabis Res. 2020 Oct 2;2(1):33. doi: 10.1186/s42238-020-00044-y.
4
Healthcare Professionals' Perceptions About Medical Cannabis in Greece: A Qualitative Study.希腊医疗保健专业人员对医用大麻的看法：一项定性研究。
J Mark Access Health Policy. 2025 Apr 2;13(2):13. doi: 10.3390/jmahp13020013. eCollection 2025 Jun.
5
Implications of the 2018 Canadian Cannabis Act: Should regulation differ for medicinal and non-medicinal cannabis use?⋆.2018 年加拿大《大麻法案》的影响：医用和非医用大麻的监管是否应该有所不同？
Health Policy. 2021 Jan;125(1):12-16. doi: 10.1016/j.healthpol.2020.10.016. Epub 2020 Nov 11.
6
Issues in the establishment of a therapeutic cannabis market under Jamaica's Dangerous Drugs Amendment Act 2015.根据牙买加2015年《危险药物修正案》建立医用大麻市场的相关问题。
Int J Drug Policy. 2020 Sep 15;86:102945. doi: 10.1016/j.drugpo.2020.102945.
7
L. from Seized Drug Material: Germination and Establishment.L. 来自缴获的毒品材料：发芽和建立。
Cannabis Cannabinoid Res. 2024 Jun;9(3):e924-e932. doi: 10.1089/can.2022.0305. Epub 2023 Aug 23.
8
Association of recreational cannabis legalization with changes in medical, illegal, and total cannabis expenditures in Canada.加拿大娱乐用大麻合法化与医疗、非法及大麻总支出变化的关联。
Int J Drug Policy. 2025 May;139:104793. doi: 10.1016/j.drugpo.2025.104793. Epub 2025 Apr 5.
9
Medical cannabis laws lower individual market health insurance premiums.医用大麻合法化降低了个人医保保费。
Int J Drug Policy. 2023 Sep;119:104143. doi: 10.1016/j.drugpo.2023.104143. Epub 2023 Aug 10.
10
Bridging the gap: Exploring consumer experiences and motivations for transitioning between illicit and regulated cannabis markets.弥合差距：探索消费者在非法大麻市场和合法大麻市场之间转换的经历与动机。
Int J Drug Policy. 2024 Dec;134:104644. doi: 10.1016/j.drugpo.2024.104644. Epub 2024 Nov 2.
本文引用的文献
1
Medical cannabis for children: Evidence and recommendations.儿童医用大麻：证据与建议。
Paediatr Child Health. 2024 Apr 5;29(2):104-121. doi: 10.1093/pch/pxad078. eCollection 2024 May.
2
On activism and knowledge: the experience of cannabis associations in Brazil.论行动主义与知识：巴西大麻协会的经验。
Cien Saude Colet. 2024 Feb;29(2):e18462022. doi: 10.1590/1413-81232024292.18462022. Epub 2023 May 17.
3
[Judicialization of cannabidiol-based products in Brazil: an analysis from 2019 to 2022].[巴西基于大麻二酚产品的司法化：2019年至2022年的分析]
Cad Saude Publica. 2023 Oct 9;39(8):e00024723. doi: 10.1590/0102-311XPT024723. eCollection 2023.
4
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.权衡使用大麻的风险和益处：对随机对照试验和观察性研究的荟萃分析进行伞式综述。
BMJ. 2023 Aug 30;382:e072348. doi: 10.1136/bmj-2022-072348.
5
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.医用大麻素：基于药理学的系统评价和荟萃分析，涵盖所有相关医学适应证。
BMC Med. 2022 Aug 19;20(1):259. doi: 10.1186/s12916-022-02459-1.
6
Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies.长期和严重的医用大麻和大麻素对慢性疼痛的危害：非随机研究的系统评价。
BMJ Open. 2022 Aug 4;12(8):e054282. doi: 10.1136/bmjopen-2021-054282.
7
"Is medical cannabis safe for my patients?" A practical review of cannabis safety considerations.“医用大麻对我的患者安全吗？” 对大麻安全性的实用考量的综述。
Eur J Intern Med. 2021 Jul;89:10-18. doi: 10.1016/j.ejim.2021.05.002. Epub 2021 May 31.
8
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.精神障碍的药用大麻：以临床为重点的系统评价。
BMC Psychiatry. 2020 Jan 16;20(1):24. doi: 10.1186/s12888-019-2409-8.
Zotero 插件